drugset / Trial / NCT01857479
A Randomized Controlled Trial of Inhaled Amphotericin B for Maintaining Remission in Allergic Bronchopulmonary Aspergillosis
Phase 2/3
Completed
21 enrolled
Post Graduate Institute of Medical Education and Research, Chandigarh
RandomizedParallel-groupOpen-labelTreatment
Summary
Inhaled amphotericin, a antifungal drug would decrease Aspergillus colonization and decrease the occurrence of exacerbations of Allergic Bronchopulmonary Aspergillosis (ABPA).
Timeline
- Start
- 2013-05
- Primary completion
- 2015-06
- Completion
- 2015-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Amphotericin B | Unknown | 10 mg | Inhaled |
| Background | Budesonide | Small molecule | 1 mg | Inhaled |